IMA402

IMA402 · Immatics Biotechnologies GmbH

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMA402, covering 2025-11-18 to 2025-11-18. Get the full timeline:

Most recent: Clinical Trial Update: IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors [Phase 1, Phase 2]